Drug maker Lupin on Tuesday said it has inked a licensing pact with Alvion Pharmaceuticals to commercialise medicines for cardiometabolic diseases in Southeast Asia.
The Mumbai-based company said it is committed to providing affordable treatment options to healthcare providers and patients.
By commercialising cardiometabolic drugs in Southeast Asia, Lupin will play a significant role in improving the quality of healthcare and access to medicines, it added.
"Forming a long-term collaboration with Alvion to launch a range of therapies will allow Lupin to expand its footprint across Southeast Asia with quality cost effective alternatives for patients and the healthcare system," Lupin Regional Head Southeast Asia Gabriel Georgy said in a statement.
Both companies have a solid track record of developing and launching products and this agreement will further cement Lupin as a formidable pharmaceutical company in the region, he added.
"Being a leader in value-added medicines, Alvion shall support Lupin's activities aiming to position both companies at the forefront for both molecules," Alvion CEO John Bouros said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU